Captrust Financial Advisors Mannkind Corp Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.34 - $4.29 $298,238 - $383,066	-89,293 Reduced 75.24%	29,387 $106,000
Q3 2023 Nov 14, 2023	SELL	$3.91 - $5.45 $445,915 - $621,545	-114,045 Reduced 49.0%	118,680 $490,000
Q2 2023 Aug 14, 2023	BUY	$3.72 - $4.79 $865,737 - $1.11 Million	232,725 New	232,725 $947,000
Q2 2022 Aug 16, 2022	BUY	$2.67 - $4.77 $1,068 - $1,907	400 New	400 $2,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.44 $2,379 - $3,294	-2,288 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$1.09 - $1.88 $2,493 - $4,301	2,288 New	2,288 $3,000

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.